NEUMORA THERAPEUTICS INC. - COMMON STOCK

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

28 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

04 Mar 2025 08:30:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

03 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces Leadership Transition

13 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

02 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in November

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders

14 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation

20 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

07 May 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in May

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

15 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days

13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

22 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire